Summary
This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study
consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in
combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX
and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2)
for CC-220 monotherapy and CC-220 in combination with DEX for Relapsed Refractory Multiple
Myeloma (RRMM), CC-220 in combination with DEX and BTZ, and CC-220 in combination with DEX
and DARA for Newly Diagnosed Multiple Myeloma (NDMM).